Alnylam’s big Phase 3 win; LGBTQ+ leaders charting paths; Chevron overturned; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

This week had everything: highly anticipated trial readouts, Supreme Court decisions, groundbreaking gene editing research and some Biogen gossip. Note that next week, due to the July 4 holiday, we will only be publishing our three daily newsletters Monday through Wednesday. We’re off on the Fourth and will be sending one newsletter on Friday around 11:30 a.m. Eastern time.

Alnylam’s big Phase 3 win

Alnylam cleared a closely-watched, make-or-break Phase 3 trial for vutrisiran, which could become the first RNA silencing therapy on the market for ATTR amyloidosis with cardiomyopathy. The drug, which is already approved as Amvuttra for another manifestation of ATTR amyloidosis, reduced…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks